mRNA-1010.4
- Generic Name
- mRNA-1010.4
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05868382
- Locations
- 🇺🇸
DM Clinical Research, Sugar Land, Texas, United States
🇺🇸Meridian Clinical Research, Lincoln, Nebraska, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath